Market: NASD |
Currency: USD
Address: 1185 Avenue of the Americas
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
Show more
📈 Petros Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
-
💰 Dividend History
Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
2025 |
- |
$0.040000 |
- |
2025-05-01 |
- |
Stock split |
Total Amount for 2025: $0.040000 |
2022 |
- |
$0.100000 |
- |
2022-12-01 |
- |
Stock split |
Total Amount for 2022: $0.100000 |
📅 Earnings & EPS History for Petros Pharmaceuticals, Inc.
Date | Reported EPS |
---|
2024-11-13 | -13.25 |
2024-08-14 | -9.25 |
2024-05-15 | -42.25 |
2024-04-01 | -54.25 |
📰 Related News & Research
No related articles found for "petros pharmaceuticals".